Dose-dependent protection on cisplatin-induced ototoxicity - An electrophysiological study on the effect of three antioxidants in the Sprague-Dawley rat animal model

Medical Science Monitor

Volumn 17, Issue 8, 2011, Pages

  Lorito, Guiscardo ^a   Hatzopoulos, Stavros ^a   Laurell, Göran ^b   Campbell, Kathleen C M ^c   Petruccelli, Joseph ^d   Giordano, Pietro ^a   Kochanek, Krzysztof ^e   Sliwa, Lech ^e   Martini, Alessandro ^a   Skarzynski, Henryk ^e  

^a UNIVERSITY OF FERRARA   (Italy)

^b UMEÅ UNIVERSITY   (Sweden)

^c SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Life Science and Bioengineering Center   (United States)

^e INSTITUTE OF PHYSIOLOGY AND PATHOLOGY OF HEARING   (Poland)

Author keywords

Auditory brainstem responses; Cisplatin ototoxicity; D methionine; Distortion product otoacoustic emissions; Ebselen; N L acetylcysteine

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; CISPLATIN; EBSELEN; METHIONINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISTORTION PRODUCT OTOACOUSTIC EMISSION; ELECTROPHYSIOLOGY; EVOKED BRAIN STEM AUDITORY RESPONSE; FOLLOW UP; HEARING; MALE; NONHUMAN; OTOTOXICITY; RAT; TREATMENT OUTCOME;

EID: 80051512581     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.881894     Document Type: Article

References (57)

1. Gandara DR, Perez EA, Weibe V, DeGregorio MW: Cisplatin chemoprotectionand rescue: Pharmacologic modulation of toxicity. Sem Oncol,1991;18: 49-55
2. Kersten L, Braunlich H, Keppler BK et al: Comparative nephrotoxicityof some antitumour active platinum and rutherium complexes in rats. J Appl Toxicol, 1998; 18: 93-101
3. Husain K, Morris C, Whitworth C et al: Protection by ebselen against cisplatin-induced nephrotoxicity: antioxidant system. Mol Cell Biochem,1998; 178: 127-33
4. Ueda H, Sugiyama K, Tashiro S, Yokota M: Mechanism of the protectiveeffect of sodium malate on cisplatin-induced toxicity in mice. BiolPharm Bull, 1998; 16: 234-67
5. Sumegi B, Deres P: Use of PARP inhibitors to counteract the side effectsof cytotoxic drugs. Med Sci Monit, 2003; 9(Suppl.1): 65
6. Fausti SA, Schechter MA, Rappaport BZ, Frey RH: Early detection ofcisplatin ototoxicity. Cancer, 1984; 53: 224-31
7. Fausti SA, Frey RH, Henry JA et al: Early detection of ototoxicity usinghigh-frequency tone burst-evoked auditory brainstem responses. J AmAcad Audiol, 1992; 3: 397-404
8. Kohn SM, Fradis J, Zidan L et al: Cisplatin ototoxicity in guinea pigs withspecial reference to toxic effects in the stria vascularis. Laryngoscope,1988; 98: 871-85
9. Blakley BW, Gupta AK, Myers SF, Schwan S: Risk factors for ototoxicitydue to cisplatin. Arch Otoryngol Head Neck Surg, 1994; 120: 541-46
10. Saito T, Aran JM: Comparative ototoxicity of cisplatin during acute andchronic treatment. ORL, 1994; 56: 315-20
11. Ravi R, Somani S, Rybak L: Mechanism of cisplatin ototoxicity. AntioxidSyst Pharm Toxicol, 1995; 76: 384-86
12. Riggs LC, Brummett RE, Guitjens SK, Matz GJ: Ototoxicity resulting fromcombined administration of cisplatin and gentamicin. Laryngoscope,1996; 106: 401-6
13. Campbell CM, Rybak LP, Meech RP, Hughes L: D-methionine providesexcellent protection from cisplatin ototoxicity in the rat. Hear Res, 1996;102: 90-98
14. Kopelman J, Budnick AS, Kramer MB, Sessions RB: Ototoxicity of highdosecisplatin by bolus administration in patients with advanced cancersand normal hearing. Laryngoscope, 1988; 98: 858-64
15. Laurell G, Jungnelius U: High dose cisplatin treatment. Hearing lossand plasma concentrations. Laryngoscope, 1990; 100: 724-34
16. Laurell G, Bagger-Sjöbäck D: Degeneration of the organ of Corti followingintravenous administration of cisplatin. Acta Otolaryngol, 1991;111: 891-98
17. Laurell G, Engström B: The ototoxic effect of cisplatin on guinea pigsin relation to dosage. Hear Res, 1989; 38: 27-33
18. Taudy M, Syka J, Popelar J, Ulehlova L: Carboplatin and cisplatin ototoxicityin guinea pigs. Audiology, 1992; 31: 293-99
19. Stengs CH, Klis SF, Huizing EH, Smoorenburg GF: Protective effcts ofa neurotrophic ACTH(4-9) analog on cisplatin ototoxicity in relationto the cisplatin dose: an electrocochleographic study in albino guineapigs. Hear Res, 1998; 124: 108-17
20. Tange R, Vuzevski VD: Changes in the stria vascularis of the guinea pigdue to cis-platinum. Arch. Otorhinolaryngol, 1982; 239: 41-47
21. Tange R, Conijin A, Van Zeig IL: Cortitoxic effects of cisplatin in theguinea pig. Arch Otorhinolaryngol, 1982; 237: 17-26
22. Meech RP, Campbell KC, Hughes LP, Rybak LP: A SemiquantitativeAnalysis of the Effects of Cisplatin on the Rat Stria Vascularis. Hear Res,1988; 124: 44-59
23. Campbell KC, Meech RP, Rybak LP, Hughes LF: D-Methionine protectsagainst cisplatin damage to the stria vascularis. Hear Res, 1999;138: 13-28
24. Gabaizadeh R, Staecker H, Liu W et al: Protection of both auditoryhair cells and auditory neurons from cisplatin-induced damage. Actaotolaryngol, 1997; 117: 232-38
25. Campbell KC, Meech RP, Rybak LP, Hughes LF: The effect ofD-methionine on cochlear oxidative state with and without cisplatinadministration: Mechanisms of otoprotection. J Am Acad Audiol, 2003;14: 144-56
26. Campbell KC, Meech RP, Klemens JJ et al: Prevention of Noise- and Drug-Induced Hearing Loss with D-methionine Hearing Res, 2007;226: 92-103
27. Reser D, Rho M, Dewan D et al: L- and D-Methionine Provide Equivalent Long Term Protection Against cisplatin-Induced Ototoxicity In Vivo,With Partial In Vitro and In Vivo Retention of Antineoplastic Activity. Neurotoxicology, 1999; 20: 731-48
28. Li G, Frenz DA, Brahmblatt S et al: Round window membrane deliveryof L-methionine provides protection from cisplatin ototoxicity withoutcompromising chemotherapeutic efficacy. NeuroToxicol, 2001; 22:163-76
29. Korver KD, Rybak LP, Whitworth CA, Campbell KC: Round window applicationof D-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg, 2002; 126: 683-89
30. Wimmer C, Mees, K, Stumpf P et al: Round Window Application ofD-methionine, sodium thiosulfate, brain-derived neurotrophic factor,and fibroblast growth factor-2 in Cisplatin-induced ototoxicity. OtolNeurotol, 2004; 25: 33-40
31. Lempers E, Reedijk J: Reversibility of binding of cisplatin-methioninein proteins by diethyldithiocarbamate or thiourea: a study of model adducts.Inorg Chem, 1990; 29: 217-22
32. Vogt J: Oxidation of methionyl residues in proteins: tools, targets andreversal. Free Radic Biol Med, 1995; 18: 93-105
33. Cloven NG, Re A, McHale M et al: Evaluation of D-Methionine as a cytoprotectantin cisplatin treatment of an animal model for ovarian cancer.Anti Cancer Research, 2000; 20: 4205-10
34. Vuyyuri SB, Hamstra DA, Khanna D et al: Evaluation of a D-Methionineas a Novel Oral Radioprotector for Prevention of Mucositis. ClinicalCancer Research, 2008; 14(7): 2161-70
35. Ekborn A, Laurell G, Johnström P et al: D-Methionine and cisplatinototoxicity in the guinea pig: D-methionine influences cisplatin pharmacokinetics.Hear Res, 2002; 165: 53-61
36. Deegan PM, Pratt IS, Ryan MP: The nephrotoxicity, cytotoxicity andrenal handling of a cisplatin-methionine complex in male Wistar rats.Toxicology, 1994; 25: 1-14
37. Najafi A, Mojtahedzadeh M, Mahmoodpoor A et al: Effect ofN-acetylcysteine on microalbuminuria in patients with acute respiratorydistress syndrome. Arch Med Sci, 2009: 5(3): 408-14
38. Dickey DT, Muldoon LL, Kraemer DF, Neuwelt EA: Protection againstcisplatin-induced ototoxicity by N-acetylcysteine in a rat model. HearRes, 2004; 193: 25-30
39. Rybak LP, Somani S: Ototoxicity. Amelioration by protective agents.Ann N Y Acad Sci, 1999; 884: 143-51
40. Lynch ED, Gu R, Pierce C, Kil J: Reduction of acute cisplatin ototoxicityand nephrotoxicity in rats by oral administration of allopurinol andebselen. Hear Res, 2005; 201: 81-89
41. Pourbakht A, Yamasoba T: Ebselen attenuates cochlear damage causedby acoustic trauma. Hear Res, 2003; 181: 100-8
42. Hatzopoulos S, Petruccelli J, Laurell G et al: Electrophysiological findingsin the Sprague-Dawley rat induced by moderate-dose carboplatin.Hear Res, 2003; 182: 48-55
43. Lorito G, Giordano P, Prosser S et al: Noise-induced hearing loss: astudy on the pharmacological protection in the Sprague Dawley ratwith N-acetyl-cysteine. Acta Otorhinolaryngol Ital, 2006; 133-39
44. Lorito G, Giordano P, Petruccelli J et al: Different strategies in treatingnoiseinduced hearing loss with N-acetylcysteine. Med Sci Monit, 2008;14(8): BR159-64
45. Hatzopoulos S, Di Stefano M, Campbell KC et al: Cisplatin ototoxicityin the Sprague Dawley rat evaluated by distortion product otoacousticemissions. Audiology, 2001; 40: 253-64
46. Hatzopoulos S, Petruccelli J, Laurell G et al: Evaluation of anesthesia effectsin a rat animal model using otoacoustic emission protocols. HearRes, 2002; 170: 12-21
47. Hatzopoulos S, Petruccelli J, Laurell G et al: Ototoxic effects of cisplatinin a Sprague Dawley rat animal model as revealed by ABR and transientlyevoked otoacoustic emission measurements. Hear Res, 2002;170: 70-82
48. Giordano P, Lorito G, Ciorba A et al: Protection against cisplatin ototoxicityin a Sprague-Dawley rat animal model, Acta OtorhinolaryngolItal, 2006; 26: 198-207
49. Whitehead ML, Lonsbury-Martin BL, Martin GK: Evidence for two discretesources of 2f1-f2 distortion-product otoacoustic emission in rabbit.II: Differential physiological vulnerability. J Acoust Soc Am, 1992;92: 2662-82
50. Whitehead ML, McCoy MJ, Lonsbury-Martin BL, Martin GK: Dependenceof distortion-product otoacoustic emissions on primary levels in normaland impaired ears. I. Effects of decreasing L2 below L1. J AcoustSoc Am, 1995; 97: 2346-58
51. Huang T, Cheng A, Stupak H et al: Oxidative Stress-induced Apoptosisof Cochlear Sensory Cells: Otoprotective Strategies. Int J Dev Neurosci,2000; 18: 259-70
52. Theneshkumar S, Lorito G, Giordano P et al: Effect of noise conditioningon cisplatin-induced ototoxicity: a pilot study. Med Sci Monit, 2009;15(7): BR173-77
53. Duan M, Laurell G, Qui J, Borg E: Susceptibility to impulse noise indifferent species: guinea pig, rat and mouse. Acta Otolaryngol, 2008;128(3): 277-83
54. Robbins KT, Storniolo AM, Kerber C et al: Phase I study of highly selectivesupradose cisplatin infusions for advanced head and neck cancer.J Clin Oncol, 2002; 12: 2113-20
55. Laurell G, Andersson A, Engström B, Ehrsson H: Distribution of cisplatinin perilymph and cerebrospinal fluid after intravenous administrationin the guinea pig. Cancer Chemother Pharmacol, 1995; 36: 83-86
56. Videhult PP, Engmer C, Wallin I et al: High concentrations of thiosulfatein scala tympani perilymph after systemic administration in theguinea pig. Acta Otolaryngol, 2009; 129(2): 132-37
57. Laurell G, Teixeira M, Sterkers O et al: Local administration of antioxidantsto the inner ear. Kinetics and distribution. Hear Res, 2002; 173:198-209